Decubitus Care - Call for a Clinical Study Site

Proposal:

Quellent is soliciting clinicians interested in conducting clinicals that would study the use of Quellent's Stay DriPADs on patients at risk of pressure sores to determine if the use of DriPADs causes a delay in the onset of decubiti and/or results in a reduced incidence/severity of ulcers.

Perspective:

The management of the pressure points on the patient is generally accepted as the most critical issue in caring for patients at risk of pressure sores. However, Quellent believes that the management of the moisture and bacterial load in the environment may also play a significant role in delaying the start of ulceration and reducing the severity of the ulcer. Quellent's Stay DriPADs incorporate an Antimicrobial Agent within the core matrix to control the bacteria within the pad, and its proprietary Stay-Dri fabric cover maintains a very dry environment for the patient as well. It is the company's hope that a clinical study, under proper IRB and FDA supervision, may show that these factors together, control of both moisture and bioburden within a bed pad, may reduce the incidence of bed sores in patients at risk of developing them.

Proposition:

It is Quellent's proposition that Stay DriPADs could be uniquely suited for managing decubitus ulcers because they:

1. Absorb, and trap fluid within the pad, and leaving the surface of the pad dry; and
2. Have a broad-spectrum Antimicrobial Agent added to the pad to control bacteria and odors in the fluids within the pad.

If you are a clinician interested in sponsoring or participating in a clinical trial with Quellent, we will work with you, your health care facility and the appropriate regulatory agencies to develop a protocol to test this hypothesis.

Please e-mail us. or call us at:

Craig Sundheimer
Chief Business Officer
Quellent Technologies
Craig@Quellent.com
760-431-9620